This webinar is aimed at improving the end-users’ understanding of pre-clinical in vivo inflammatory bowel disease (IBD) models, addressing issues associated with the various models currently available. Dr Wilson has been working in this field for many years, working with many different biotech and pharmaceutical companies to design and perform studies that address their key questions.
This webinar will review some of the models in use and discuss current practice when running pre-clinical models for IBD drug development at Epistem. Specifically, there will be an overview of adoptive T cell transfer-mediated chronic colitis and chemically-induced models of acute colitis (DSS- and TNBS-induced colitis). The following key points will be addressed:
- The pros and cons of each model
- Historical data relating to disease reproducibility
- Performance of reference items / clinical standards
- A summary of typical study designs employed for each model
The aim of this webinar is to enable the end-user to select the best model and study design for their research.
Dr. James Wilson, Principal Scientist, Epistem.
Dr. Wilson received his PhD in Pharmacology and Toxicology from the University of London (Royal Postgraduate Medical School) in 1992. Subsequently, Dr. Wilson spent 14 years within research, working at the University of Manchester, Astra Zeneca, The Paterson Institute for Cancer Research and Bart’s and The London School of Medicine and Dentistry . Throughout his career, Dr. Wilson’s research focus has been on the cell and molecular biology of epithelial cells and tissues. He joined the Contract Research Services Division at Epistem Limited in 2006 where he has developed, validated and managed Epistem’s pre-clinical Inflammatory Bowel Disease (IBD) portfolio.
Who Should Attend?
Chief Scientific Officers (CSO), Senior Executives, Directors, Team Leaders and Senior Scientists involved in understanding, predicting or controlling off-target or on-target/off-tissue toxicity to the intestinal epithelium.
Relevant job areas or roles:
- Pre-clinical Development
- Pre-clinical Pharmacology
- Pre-clinical Research
- Pre-clinical Drug Development
- Discovery Scientists
- Pharmaceutical Toxicologists
Epistem is a biotechnology company with a specialist understanding of epithelial tissue and stem cell analyses, operating three distinct business divisions.
The Contract Research Division delivers innovative preclinical research services in the areas of oncology (inc. leukaemia), mucositis, inflammatory bowel disease, rheumatoid arthritis, wound healing and skincare. Working with over 200 Pharmaceutical, biotechnology, and personal care companies worldwide, it offers proprietary assays for target validation, screening, efficacy, and translational biology using some of the latest technology, including small animal imaging, and with a GCLP accredited histology suite.
The Personalised Medicine Division is committed to facilitating a more tailored approach to patient treatment and care. It applies innovative gene expression technology to discovering novel drug-induced biomarkers to GCLP standard. It has also developed Genedrive™, a ‘point of care’ molecular diagnostic device, providing a ‘near patient’ diagnosis in less than 30 minutes using hand held apparatus.
Our Novel Therapies Division is identifying the key regulators (proteins and peptides) of epithelial stem cells with the aim of developing therapeutics to control cell production.